
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : XL-001
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : French Government
Deal Size : $2.7 million
Deal Type : Funding
Allogenica Wins €2.5M Grant for Universal CAR-T Therapy Advancement
Details : The funding will help accelerate the industrialization of Allogenica’s lead-candidate CAR-T, called the XL-001 for treating CD19-positive blood cancers.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
March 19, 2025
Lead Product(s) : XL-001
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : French Government
Deal Size : $2.7 million
Deal Type : Funding
